Special chemistry – Page 6

09 Jun

5-HYDROXYINDOLEACETIC ACID, 24 HR URINE

June 9, 2023June 9, 2023vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

TUMOR MARKER

Synonyms/Aliases

5-OH-INDOLEACETIC ACID.

Abbreviations

5-HIAA

^Type

INDIVIDUAL TEST

^Results

RESULTS READY/ REPORTED IN 7 WORKING DAYS

^Method

CHROMATOGRAPHY.

^Temp

REFRIGERATED. ROOM (AMBIENT) TEMPERATURE IS NOT ACCEPTABLE

^Setup

BATCHED.

Components Parameters

NOT APPLICABLE.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. TOTAL VOLUME OF COLLECTED 24 HOUR URINE IS REQUIRED. PROVIDE CLINICAL HISTORY & PATIENT'S CURRENT DRUG HISTORY (MULTIPLE DRUGS CAN INCREASE OR DECREASE 5-HIAA LEVELS; CONSULT PATHOLOGIST IF IN DOUBT).

Patient preparation

ACCURATELY TIMED 24 HOUR COLLECTION (E.G. 6A.M., DAY 1 TO 6A.M., DAY 2) IS CRUCIAL FOR RESULT ACCURACY. COLLECT URINE IN A CLEAN WIDE MOUTH CONTAINER & TRANSFER ENTIRE COLLECTION INTO THE CONTAINER THAT WAS PROVIDED BY THE LAB. REFRIGERATE DURING COLLECTION. KEEP OUT OF REACH OF CHILDREN (CONTAINS CORROSIVE SUBSTANCES). DO NOT CONSUME FOODS RICH IN SEROTONIN (E.G. AVOCADOS, BANANAS, PINEAPPLE, MELONS, TOMATOES, EGGPLANTS, NUTS ETC.) FOR 48-72 HOURS PRIOR TO SAMPLE COLLECTION. AVOID STRENUOUS EXERCISE.

Sample type

24 HOUR URINE. TO BE KEPT IN DARK E.G. IN DARK CONTAINER OR WRAPPED IN ALUMINIUM FOIL.

Container/ preservative

CLEAN CONTAINER WITH 10ML OF 6N HCL PRESERVATIVE ISSUED BY THE LAB.

Sample volume

10ML ALIQUOT OF 24 HOUR URINE. ORIGINAL (TOTAL) VOLUME IN ML MUST BE SPECIFIED ON THE REQUEST FORM.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE (E.G. SPOT URINE SAMPLES; EXPOSED TO LIGHT; WITHOUT PRESERVATIVE); INSUFFICIENT SAMPLE.

Other Instructions

- N/A

Reference intervals

AGE & GENDER APPROPRIATE VALUES ARE PROVIDED ON THE REPORT.

Clinical Utility

A SEROTONIN METABOLITE & TUMOR MARKER USED IN THE DIAGNOSIS & MONITORING OF CARCINOID TUMORS.

Test Limitations/ Confounders

DIETARY & DRUG RESTRICTIONS APPLY. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS & RESULTS OF OTHER DIAGNOSTIC WORK-UP E.G. IMAGING, TISSUE BIOPSY FINDINGS.

09 Jun

25-HYDROXY VITAMIN D

June 9, 2023June 9, 2023vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

ENDOCRINE

Synonyms/Aliases

25-OH VITAMIN D; 25-HYDROXYCHOLECALCIFEROL.

Abbreviations

D2, D3

^Type

INDIVIDUAL TEST

^{7 Days}

RESULTS READY/ REPORTED IN3 HOURS

^Method

IMMUNOASSAY

^Temp

REFRIGERATED (2℃-8℃).

^Setup

DAILY

Components Parameters

NOT APPLICABLE.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

NO PREPARATION REQUIRED

Sample type

SERUM.

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 2ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

CENTRIFUGE SST (SERUM GEL TUBES) WITHIN 1-2 HOURS OF COLLECTION. CENTRIFUGE RED TOP VACUTAINERS AND ALIQUOT SERUM WITHIN 1-2 HOURS OF COLLECTION. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Reference intervals

VALUES DEFINING SUFFICIENT & INSUFFICIENT LEVELS ARE PROVIDED ON THE REPORT.

Clinical Utility

DIAGNOSIS OF VITAMIN D DEFICIENCY AND MONITORING SUPPLEMENTATION IN PATIENTS WITH BONE DISEASES SUCH AS RICKETS AND OSTEOMALACIA.

Test Limitations/ Confounders

RESULTS INFLUENCED BY RECENT INGESTION OF VITAMIN D SUPPLEMENTS (TEST THEN TREAT & NOT VICE VERSA).

09 Jun

1,25-DIHYDROXYVITAMIN D

June 9, 2023June 9, 2023vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

ENDOCRINE

Synonyms/Aliases

CALCITRIOL; 1,25(OH)2 VITAMIN D; 1,25 DIHYDROXY CHOLECALCIFEROL.

Abbreviations

VIT D 1,25

^Type

INDIVIDUAL TEST

^{7 Days}

RESULTS READY/ REPORTED IN 5 WORKING DAYS.

^Method

IMMUNOASSAY

^Temp

REFRIGERATED (2℃-8℃).

^Setup

BATCHED.

Components Parameters

NOT APPLICABLE.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

FASTING PREFERRED. (NO SPECIAL PREPARATION REQUIRED)

Sample type

SERUM.

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 2ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

Reference intervals

AGE & GENDER APPROPRIATE VALUES ARE PROVIDED ON THE REPORT.

Clinical Utility

THIS TEST MEASURES THE BIOACTIVE FORM OF VITAMIN D. IT IS USED IN THE DIFFERENTIAL DIAGNOSIS OF HYPOCALCEMIA AND TO MONITOR PATIENTS WITH RENAL OSTEODYSTROPHY OR CHRONIC RENAL FAILURE.

Test Limitations/ Confounders

IMMUNOASSAY INTERFERENCE CAN GIVE RISE TO SPURIOUS RESULTS. SUCH INTERFERENCE CAN ARISE FROM PRESENCE OF HETEROPHILE ANTIBODIES, ANTI-ANIMAL ANTIBODIES, AUTOANTIBODIES, PARAPROTEINS, BIOTIN ETC. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS.

07 Jun

N-TERMINAL PROHORMONE OF BRAIN NATRIURETIC PEPTIDE

June 7, 2023June 7, 2023vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

CARDIAC ASSESSMENT.

Synonyms/Aliases

N-TERMINAL PROBNP.

Abbreviations

NT PRO BNP; NT-proBNP.

^Type

INDIVIDUAL TEST.

^{2-3 Days}

RESULTS READY/ REPORTED IN 2-3 WORKING DAYS.

^Method

IMMUNOASSAY.

^Temp

AMBIENT (25℃): 1 DAY; R (2℃-8℃): 3 DAYS; F (-20℃): 14 DAYS.

^Setup

BATCHED.

Components Parameters

NOT APPLICABLE.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

NOT APPLICABLE.

Sample type

SERUM.

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 2 ML.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

CARDIAC BIOMARKER USEFUL FOR DIAGNOSIS & PROGNOSTICATION OF HEART FAILURE.

Test Limitations/ Confounders

07 Jun

N-TELOPEPTIDE, CROSS-LINKED, URINE

June 7, 2023June 7, 2023vincentochiengde

Category

ROUTINE CHEMISTRY.

Sub Category

METABOLIC.

Synonyms/Aliases

CROSSLINKED N-TELOPEPTIDE OF TYPE 1 COLLAGEN; N-TELOPEPTIDE, URINE; NTX-TELOPEPTIDE; COLLAGEN CROSSLINKS.

Abbreviations

NTx.

^Type

INDIVIDUAL TEST.

^{10 Days}

RESULTS READY/ REPORTED IN 10 WORKING DAYS.

^Method

IMMUNOASSAY.

^Temp

AMBIENT, 24-72 HOURS; REFRIGERATED, 2-8ºC, 7 DAYS; FROZEN, 30 DAYS.

^Setup

BATCHED.

Components Parameters

NOT APPLICABLE.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. TOTAL 24 HOUR URINE VOLUME (ML) IS REQUIRED.

Patient preparation

Sample type

24 HOUR URINE.

Container/ preservative

CLEAN, LEAK PROOF CONTAINER, NO PRESERVATIVE. REFRIGERATE DURING COLLECTION.

Sample volume

10ML ALIQUOT OF 24 HOUR URINE WITHOUT PRESERVATIVE. ORIGINAL (TOTAL) VOLUME IN ML MUST BE SPECIFIED ON THE REQUEST FORM.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; 24 HOUR URINE VOLUME NOT PROVIDED.

Other Instructions

ACCURACY OF RESULTS IS DEPENDENT ON COMPLETE COLLECTION & ACCURATE TIMING OF THE 24 HOUR URINE SAMPLE.

Reference intervals

AGE AND GENDER APPROPRIATE VALUES PROVIDED WITH REPORT.

Clinical Utility

BONE RESORPTION MARKER FOR DIAGNOSIS OF METABOLIC BONE DISORDERS OR DISORDERS ASSOCIATED WITH INCREASED BONE TURNOVER (E.G. OSTEOPENIA, HIGH TURNOVER OSTEOPOROSIS, PAGET DISEASE, METASTATIC BONE DISEASE ETC.). MONITORING RESPONSE TO ANTI-RESORPTIVE THERAPY.

Test Limitations/ Confounders

TO AVOID BIOTIN INTERFERENCE, AVOID BIOTIN CONTAINING MULTIVITAMINS & SUPPLEMENTS FOR AT LEAST 24 HOURS PRIOR TO COLLECTION.

07 Jun

METHYLMALONIC ACID, QUANTITATIVE, SERUM

June 7, 2023June 7, 2023vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

ANEMIA & NUTRITION.

Synonyms/Aliases

METHYLMALONATE, SERUM.

Abbreviations

MMA.

^Type

INDIVIDUAL TEST.

^{7 Days}

RESULTS READY/ REPORTED IN 7 WORKING DAYS.

^Method

LC-MS/MS.

^Temp

R (2℃-8℃):3D; F (-20℃):14D. SAMPLES AT ROOM TEMPERATURE ARE NOT ACCEPTABLE.

^Setup

BATCHED.

Components Parameters

NOT APPLICABLE.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

NOT APPLICABLE.

Sample type

SERUM (SEPARATE THE SAMPLE WITHIN 1 HOUR AFTER COLLECTION).

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 3MLSEPARATED WITHIN 1 HOUR AFTER COLLECTION.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

Reference intervals

AGE & GENDER APPROPRIATE VALUES ARE PROVIDED ON THE REPORT.

Clinical Utility

DIAGNOSE AND MONITOR METHYLMALONIC ACIDEMIA AND LATENT VITAMIN B12 DEFICIENCY (BORDERLINE LOW VITAMIN B12 LEVELS).

Test Limitations/ Confounders

DIET AND NUTRITIONAL STATUS INFLUENCE LEVELS.

07 Jun

METANEPHRINES, FREE, PLASMA

June 7, 2023June 7, 2023vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

TUMOR MARKER.

Synonyms/Aliases

FRACTIONATED METANEPHRINES, PLASMA; PLASMA METANEPHRINES.

Abbreviations

N/A.

^Type

PROFILE/ PANEL (BUNDLED TESTS).

^{10 Days}

RESULTS READY/ REPORTED IN 10 WORKING DAYS.

^Method

CHROMATOGRAPHY.

^Temp

FROZEN (PREFERRED). AMBIENT/ ROOM TEMPERATURE NOT ACCEPTABLE.

^Setup

BATCHED.

Components Parameters

NORMETANEPHRINE & METANEPHRINE.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. PROVIDE CLINICAL HISTORY & PATIENT'S CURRENT DRUG HISTORY. DISCONTINUE ANTIHYPERTENSIVE DRUGS IF FEASIBLE (MULTIPLE DRUGS CAN INCREASE OR DECREASE METANEPHRINE LEVELS; CONSULT PATHOLOGIST IF IN DOUBT).

Patient preparation

DISCONTINUE HYPERTENSION RELATED MEDICATION (TO BE DECIDED BY ATTENDING DR/ CLINICIAN). DO NOT CONSUME FOODS RICH IN SEROTONIN (E.G. BANANAS, PINEAPPLE, CEREALS, POTATOES, COFFEE, TEA, CHOCOLATE, VANILLA ETC.) FOR 72 HOURS PRIOR TO SAMPLE COLLECTION. AVOID STRENUOUS EXERCISE.

Sample type

EDTA PLASMA IMMEDIATELY SEPARATED FROM EDTA WHOLE BLOOD AND FROZEN. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Container/ preservative

EDTA (PURPLE TOP) VACUTAINER.

Sample volume

2ML EDTA PLASMA.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

PROTECT FROM DIRECT SUNLIGHT.

Reference intervals

AGE & GENDER APPROPRIATE VALUES ARE PROVIDED ON THE REPORT.

Clinical Utility

METANEPHRINES ARE METABOLITES OF CATECHOLAMINES. EVALUATION OF HYPERTENSION AND CATECHOLAMINE SECRETING TUMOURS LIKE PHEOCHROMOCYTOMA, NEUROBLASTOMA AND PARAGANGLIOMA.

Test Limitations/ Confounders

DIETARY & DRUG INTERFERENCE CAN OCCUR. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS & RESULTS OF OTHER DIAGNOSTIC WORK-UP E.G. IMAGING, TISSUE BIOPSY FINDINGS.

07 Jun

METANEPHRINES, 24 HR URINE

June 7, 2023June 7, 2023vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

TUMOR MARKER.

Synonyms/Aliases

FRACTIONATED METANEPHRINES, 24 HR URINE.

Abbreviations

N/A.

^Type

PROFILE/ PANEL (BUNDLED TESTS).

^{7 Days}

RESULTS READY/ REPORTED IN 7 WORKING DAYS.

^Method

CHROMATOGRAPHY.

^Temp

FROZEN (PREFERRED) OR REFRIGERATED.

^Setup

BATCHED.

Components Parameters

NORMETANEPHRINE & METANEPHRINE.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. TOTAL VOLUME OF COLLECTED 24 HOUR URINE IS REQUIRED. PROVIDE CLINICAL HISTORY & PATIENT'S CURRENT DRUG HISTORY. DISCONTINUE ANTIHYPERTENSIVE DRUGS IF FEASIBLE (MULTIPLE DRUGS CAN INCREASE OR DECREASE METANEPHRINE LEVELS; CONSULT PATHOLOGIST IF IN DOUBT).

Patient preparation

ACCURATELY TIMED 24 HOUR COLLECTION (E.G. 6A.M., DAY 1 TO 6A.M., DAY 2) IS CRUCIAL FOR RESULT ACCURACY. COLLECT URINE IN A CLEAN WIDE MOUTH CONTAINER & TRANSFER ENTIRE COLLECTION INTO THE CONTAINER THAT WAS PROVIDED BY THE LAB. REFRIGERATE DURING COLLECTION. KEEP OUT OF REACH OF CHILDREN (CONTAINS CORROSIVE SUBSTANCES). DO NOT CONSUME FOODS RICH IN SEROTONIN (E.G. BANANAS, PINEAPPLE, CEREALS, POTATOES, COFFEE, TEA, CHOCOLATE, VANILLA ETC.) FOR 72 HOURS PRIOR TO SAMPLE COLLECTION. AVOID STRENUOUS EXERCISE.

Sample type

24 HOUR URINE.

Container/ preservative

CLEAN CONTAINER WITH 10ML OF 6N HCL PRESERVATIVE ISSUED BY THE LAB.

Sample volume

10ML ALIQUOT OF 24 HOUR URINE. ORIGINAL (TOTAL) VOLUME IN ML MUST BE SPECIFIED ON THE REQUEST FORM.

Rejection criteria

Other Instructions

N/A.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

METANEPHRINES ARE METABOLITES OF CATECHOLAMINES. EVALUATION OF HYPERTENSION AND CATECHOLAMINE SECRETING TUMOURS LIKE PHEOCHROMOCYTOMA, NEUROBLASTOMA AND PARAGANGLIOMA.

Test Limitations/ Confounders

DIETARY & DRUG INTERFERENCE CAN OCCUR. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS & RESULTS OF OTHER DIAGNOSTIC WORK-UP E.G. IMAGING, TISSUE BIOPSY FINDINGS.

07 Jun

MATERNAL SCREEN, SECOND TRIMESTER

June 7, 2023June 7, 2023vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

FETO-MATERNAL WELL-BEING.

Synonyms/Aliases

QUADRUPLE TEST.

Abbreviations

N/A.

^Type

PROFILE/ PANEL (BUNDLED TESTS).

^{5 Days}

RESULTS READY/ REPORTED IN 5 WORKING DAYS.

^Method

IMMUNOASSAY.

^Temp

AMBIENT (25℃): 6 HOURS; R (2℃-8℃): 2DAYS; F (-20℃): 90DAYS.

^Setup

BATCHED.

Components Parameters

AFP, HCG, ESTRIOL (E3), INHIBIN-A.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. A CLEAR & FULL ULTRASOUND REPORT MUST BE PROVIDED. MANDATORY CLINICAL DETAILS INCLUDE: LAST MENSTRUAL PERIOD (START DAY), GESTATIONAL AGE, MATERNAL WEIGHT, RACE, DATE OF BIRTH, WHETHER CONCEPTION WAS NATURAL OR THROUGH IVF, WHETHER MOTHER IS A SMOKER, WHETHER MOTHER HAS DIABETES MELLITUS, WHETHER THERE IS PERSONAL OR FAMILY HISTORY OF ANEUPLOIDY. THE TEST IS A FIRST TRIMESTER ASSESSMENT & ON THE DAY OF SAMPLE COLLECTION, GESTATIONAL AGE MUST BE BETWEEN 14 WEEKS TO 22WEEKS 6 DAYS TO BE ELIGIBLE FOR THE TEST. FOR GESTATIONAL AGE <14 WEEKS, ORDER THE DOUBLE TEST INSTEAD.

Patient preparation

N/A.

Sample type

SERUM.

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 2 ML.

Rejection criteria

>2 FETUSES (E.G. TRIPLETS, QUADRUPLETS). MISSING ULTRASOUND REPORT, WEIGHT, DATE OF COLLECTION. LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

ASSESS RISK FOR FETAL ABNORMALITIES I.E. DOWN SYNDROME (TRISOMY 21), EDWARD'S SYNDROME (TRISOMY 18) & NEURAL TUBE DEFECTS (NTDs).

Test Limitations/ Confounders

WRONG DATE OF BIRTH, MATERNAL WEIGHT, RACE, GESTATIONAL AGE, DATE OF COLLECTION WILL RESULT IN ERRONEOUS RISK ASSESSMENT. MISSING ULTRASOUND REPORT MEANS RESULTS CANNOT BE GENERATED.

07 Jun

MATERNAL SCREEN, FIRST TRIMESTER

June 7, 2023June 7, 2023vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

FETO-MATERNAL WELL-BEING.

Synonyms/Aliases

DOUBLE TEST; DOUBLE MARKER TEST.

Abbreviations

N/A.

^Type

PROFILE/ PANEL (BUNDLED TESTS).

^{7 Days}

RESULTS READY/ REPORTED IN 7 WORKING DAYS.

^Method

IMMUNOASSAY.

^Temp

AMBIENT (25℃): 6HOURS; R (2℃-8℃): 2DAYS; F (-20℃): 90DAYS

^Setup

BATCHED.

Components Parameters

FREE ß-HCG, PREGNANCY ASSOCIATED PLASMA PROTEIN A (PAPP-A).

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. A CLEAR & FULL ULTRASOUND REPORT MUST BE PROVIDED. MANDATORY CLINICAL DETAILS INCLUDE: LAST MENSTRUAL PERIOD (START DAY), GESTATIONAL AGE, MATERNAL WEIGHT, RACE, DATE OF BIRTH, WHETHER THIS WAS A NATURAL OR IVF CONCEPTION, WHETHER MOTHER IS A SMOKER, WHETHER MOTHER HAS DIABETES MELLITUS, WHETHER THERE IS PERSONAL OR FAMILY HISTORY OF ANEUPLOIDY. THE TEST IS A FIRST TRIMESTER ASSESSMENT & ON THE DAY OF SAMPLE COLLECTION, GESTATIONAL AGE MUST BE BETWEEN 8 WEEKS TO 13WEEKS 6 DAYS TO BE ELIGIBLE FOR THE TEST. FOR GESTATIONAL AGE ≥14 WEEKS, ORDER THE QUADRUPLE TEST INSTEAD.

Patient preparation

N/A.

Sample type

SERUM.

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 2 ML.

Rejection criteria

Other Instructions

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

ASSESS RISK FOR FETAL ABNORMALITIES I.E. DOWN SYNDROME (TRISOMY 21), EDWARD'S SYNDROME (TRISOMY 18) & NEURAL TUBE DEFECTS (NTDs).

Test Limitations/ Confounders

WRONG DATE OF BIRTH, MATERNAL WEIGHT, RACE, GESTATIONAL AGE, DATE OF COLLECTION WILL RESULT IN ERRONEOUS RISK ASSESSMENT. MISSING ULTRASOUND REPORT MEANS RESULTS CANNOT BE GENERATED.

1 … 4 5 6 7 8